Sign inJoin
Company / Finance

Acurx Pharmaceuticals, Inc.

ACXP · NASDAQ

Acurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution becomes the main story.

FollowAdd to WatchlistAsk Question
NASDAQACXPCoverage BootstrapBiotechnologyAntibioticsInfectious Disease
Latest ReportMay 14, 2026Acurx: the CDI antibiotic bet racing a cash clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
Nasdaq
Clear tags
Latest Thesis

Acurx: the CDI antibiotic bet racing a cash clock

Acurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution becomes the main story.

May 14, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Acurx Pharmaceuticals, Inc.the CDI antibiotic bet racing a cash clockMay 14, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Acurx: the CDI antibiotic bet racing a cash clockAcurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution becomes the main story.NASDAQMay 14, 2026Research reportReadSlides